Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
NCT01256762
Completed
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2015
Locations: Clearview Cancer Center, Huntsville, Alabama +54 locations
Conditions: Locally Recurrent or Metastatic Breast Cancer
Register for Updates
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
NCT00617370
Completed
The purpose of this study is to give a drug regimen that is hoped to be effective in preventing cancer from coming back. Since it is an aggressive breast cancer, there is a moderate to high chance that the cancer may come back. The standard treatment for this tumor type includes a chemotherapy regimen with drugs named epirubicin (E) and cyclophosphamide (C) in a vein every 2 weeks for 4 treatments, followed by a drug named paclitaxel, every 2 weeks in your vein for 4 treatments. This study is a... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/21/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Breast Cancer, Adenocarcinoma of the Breast
Register for Updates
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT00588237
Completed
The purpose of this study is to test whether it is safe to treat your cancer with 3 drugs instead of 2 drugs. After surgery, your cancer is typically treated with 2 drugs called cisplatin and paclitaxel (also known as Taxol). Cisplatin is given through a port in your belly, and Taxol is given both through the belly port and through the vein (IV). Large clinical studies have shown that this treatment gives the best results for women with your cancer. This treatment, however, also causes many side... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
Register for Updates
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
NCT01304784
Completed
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Rocky Mountain Cancer Centers, Denver, Colorado +14 locations
Conditions: HER-2 Gene Amplification
Register for Updates
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
NCT00702299
Completed
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin and paclitaxel and giving them in different ways may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of intraperito... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/02/2015
Locations: Arizona Oncology - Scottsdale, Scottsdale, Arizona +1 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
NCT00861627
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of a wild type reovirus (REOLYSIN®) in combination with paclitaxel and carboplatin is effective and safe in the treatment of Non-Small Cell Lung Cancer with KRAS or EGFR activation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2015
Locations: Georgetown University Medical Center, Washington, District of Columbia +1 locations
Conditions: Carcinoma, Non-small Cell Lung
Register for Updates
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
NCT00833807
Completed
The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma, Liver Metastasis
Register for Updates
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
NCT00568451
Terminated
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving paclitaxel together with carboplatin is more effective than giving temozolomide alone in treating patients with melanoma. PURPOSE: This phase II trial is studying the side effects and how well giving paclitaxel together with carboplatin or giving temozolomide alone works in treating patients with stage I... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
11/25/2015
Locations: Mayo Clinic Cancer Center, Rochester, Minnesota
Conditions: Melanoma (Skin)
Register for Updates
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112294
Completed
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Local Institution, Birmingham, Alabama +124 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment
NCT00807573
Completed
The purpose of this study is to determine the percentage of patients with non-small cell lung cancer that will experience a shrinkage of their tumors following treatment with three medications given together: paclitaxel, pemetrexed (Alimta®), and bevacizumab (Avastin®). Each of these medications has been approved by the FDA for patients that have not received any treatment for their lung cancer. This study is designed to study the effects of all three drugs given at the same time. Each of these... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Lung Cancer
Register for Updates
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
NCT00426556
Completed
Phase I: will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer. Phase II: will assess the efficacy and safety of the 10mg daily dose of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Wilshire Oncology Medical Group La Verne, *see Various Departments*, California +19 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
NCT01332656
Completed
Primary Objective: - To demonstrate an improvement in Progression-Free Survival (PFS) for Ombrabulin versus placebo in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with paclitaxel and carboplatin. Secondary Objectives: * To compare the overall survival (OS) between the 2 treatment arms * To compare the objective response rate (RR) between the 2 treatment arms
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/18/2015
Locations: Investigational Site Number 840007, Burbank, California +37 locations
Conditions: Ovarian Cancer Recurrent
Register for Updates